Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of DXP-106 as Monotherapy or in Combination With Standard of Care Chemotherapy in Patients With Advanced Solid Tumors.

NCT07532018 is registered in ClinicalTrials.gov with Singlomics Biopharmaceuticals Zhuhai Co., Ltd. as lead sponsor.

NCT NCT07532018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07532018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of DXP-106 as Monotherapy or in Combination With Standard of Care Chemotherapy in Patients With Advanced Solid Tumors.
Lead sponsor
Singlomics Biopharmaceuticals Zhuhai Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 23, 2026
Completion date
March 31, 2028
Enrollment
54 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, solid tumor